Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy

Gastrointestinal Stromal Tumor Clinical Trial

— ABILITY  

Official title:

Influence of an Acidic Beverage (Coca-Cola) on the Exposure to Imatinib (GLIvec) After Major gastrecTomY in Patients With Gastrointestinal Stromal Tumors (ABILITY)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02185937
• Other study ID #: ABILITY
• Status: Terminated
• Phase: Phase 1
• Start date: August 2014
• Est. completion date: November 2016

Study information

• Verified date: December 2020
• Source: Radboud University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The most common sites for GIST to occur are the stomach (60-70%) and proximal small intestines (20-25%). Therefore patients with GIST often have altered GI-tract due to tumor resection or palliative surgery which might affect imatinib exposure. Indeed, Yoo et al. showed that steady state imatinib trough levels in patients with advanced GISTs after major gastrectomy are lower compared to patients with a previous wedge resection or without gastric surgery. Patients that underwent major gastrectomy had an average imatinib plasma trough levels below 1000 µg/L. This while imatinib trough levels above 1000 µg/L are correlated to more beneficial treatment out-comes (longer Progression Free Survival).

Since imatinib easily and rapidly dissolves at pH 5.5 or less, a lack of gastric acid secretion might be causing the decreased exposure in the patients that underwent major gastrectomy.

Therefore the investigators would like to study if the exposure to imatinib in patients after major gastrectomy can be improved by creating a more acidic environment for absorption through combining imatinib intake with Coca-Cola.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients = 18 years of age

• Patients with GIST, who previously underwent major gastrectomy

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1

• Already selected to receive imatinib therapy in a dose of 400-800mg imatinib daily, as judged by the treating physician and with respect for and in agreement with the registration guidelines

• Subject is able and willing to sign the Informed Consent Form prior to screening

Exclusion Criteria:

• Concomitant administration of any anti-cancer therapies (e.g. chemo-therapy, other targeted therapy, experimental drug, etc) other than imatinib

• Concomitant use of medication which strongly inhibits or induces CYP3A4

• Refractory nausea and vomiting, malabsorption with other causes than gastrectomy or external biliary shunt that would preclude adequate absorption.

• Unwillingness to use Coca-Cola

• Unwillingness or inability to swallow whole tablets

• Inability to comply with the requirements of the protocol

• Inability to understand the nature and extent of the study and the procedures required

• Participation in a drug study within 60 days prior to the first day of this study

Related Conditions & MeSH terms

• Gastrointestinal Stromal Tumor
• Gastrointestinal Stromal Tumors
• Major Gastrectomy

Intervention

Dietary Supplement:
• cola
imatinib intake with coca-cola

Locations

Country	Name	City	State
Netherlands	Radboudumc	Nijmegen

Sponsors (1)

Lead Sponsor	Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Lubberman FJE, Gelderblom H, Wilmer CM, Kweekel DM, Desar IME, Colbers A, Burger D, van der Graaf WTA, van Erp N. Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy? Br J Clin Pharmacol. 2017 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	imatinib area under the curve	imatinib exposure assessed as area under the curve	day 7; predose - 10 hours after dosing
Secondary	number of adverse events	number of adverse events will be reported and compared for both treatments	2 weeks